| 12.91 -0.16 (-1.22%) | 09-16 14:14 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 26.31 | 1-year : | 33.28 |
| Resists | First : | 22.53 | Second : | 28.5 |
| Pivot price | 18.9  |
|||
| Supports | First : | 12.88 | Second : | 10.71 |
| MAs | MA(5) : | 13.66 |
MA(20) : | 20.65 |
| MA(100) : | 25.47 |
MA(250) : | 26.67 |
|
| MACD | MACD : | -3.7 |
Signal : | -2.9 |
| %K %D | K(14,3) : | 0.6 |
D(3) : | 1.6 |
| RSI | RSI(14): 18.2 |
|||
| 52-week | High : | 39.88 | Low : | 12.88 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ RARE ] has closed above bottom band by 24.4%. Bollinger Bands are 230.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 8 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 13.59 - 13.7 | 13.7 - 13.77 |
| Low: | 12.66 - 12.78 | 12.78 - 12.86 |
| Close: | 12.91 - 13.1 | 13.1 - 13.22 |
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative treatments for rare and ultra-rare genetic conditions. Its operations span North America, Europe, and other international markets. The company's portfolio of marketed biologic products addresses several serious diseases. This includes Crysvita (burosumab), an antibody that targets fibroblast growth factor 23, used to treat X-linked hypophosphatemia and tumor-induced osteomalacia. Mepsevii offers enzyme replacement therapy for both pediatric and adult patients suffering from Mucopolysaccharidosis VII. Dojolvi is available for individuals with long-chain fatty acid oxidation disorders, while Evkeeza (evinacumab) provides a treatment option for homozygous familial hypercholesterolemia. Ultragenyx also boasts a robust pipeline of investigational therapies. Notable candidates include DTX401, an adeno-associated virus 8 (AAV8) gene therapy for glycogen storage disease type Ia, and DTX301, another AAV8 gene therapy aimed at ornithine transcarbamylase deficiency. Other promising developments feature UX143, a human monoclonal antibody for osteogenesis imperfecta; GTX-102, an antisense oligonucleotide designed for Angelman syndrome; UX701, targeting Wilson disease; and UX053, in development for glycogen storage disease type III. To advance its research and development efforts, Ultragenyx Pharmaceutical Inc. maintains strategic collaboration and licensing agreements with numerous partners, such as Kyowa Kirin Co., Ltd., Saint Louis University, REGENXBIO Inc., Bayer Healthcare LLC, GeneTx, Mereo, University of Pennsylvania, Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc., and Daiichi Sankyo Co., Ltd. The company was founded in 2010 and operates from its headquarters in Novato, California.
Tue, 15 Sep 2026
Ultragenyx SVP sells $17,410 in common stock - Investing.com
Tue, 15 Sep 2026
Ultragenyx Pharmaceutical (RARE) Insider Sale: SVP, Chief Accounting Officer Theodore Huizenga Sells 1,283 Shares - GuruFocus
Tue, 15 Sep 2026
Theodore Alan Huizenga Sells 1,283 Shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock - MarketBeat
Tue, 15 Sep 2026
Ultragenyx (NASDAQ: RARE) executive plans $17K stock sale - Stock Titan
Mon, 14 Sep 2026
Ultragenyx Pharmaceutical (NASDAQ:RARE) Reaches New 12-Month Low - Time to Sell? - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 99 (M) |
| Shares Float | 80 (M) |
| Held by Insiders | 3.4 (%) |
| Held by Institutions | 112.5 (%) |
| Shares Short | 15,890 (K) |
| Shares Short P.Month | 13,440 (K) |
| EPS | -5.83 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -2.97 |
| Profit Margin | -81.8 % |
| Operating Margin | -35.1 % |
| Return on Assets (ttm) | -24.3 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 28.1 % |
| Gross Profit (p.s.) | -1.52 |
| Sales Per Share | 7.27 |
| EBITDA (p.s.) | -4.72 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -485 (M) |
| Levered Free Cash Flow | -222 (M) |
| PE Ratio | -2.23 |
| PEG Ratio | 0 |
| Price to Book value | -4.38 |
| Price to Sales | 1.78 |
| Price to Cash Flow | -2.64 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|